Wolverine Legal Status, FDA 503A Category, and Compounding Access

Wolverine legal status: where the FDA 503A category stands now

The Wolverine legal status question — for the BPC-157 TB-500 blend — turns on its two peptides, and that record has moved. It has not moved into an approval. One dated event also belongs here: an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026 had these peptides on its agenda as candidates for the Section 503A bulks list ^[12].

That meeting sits on top of a change in FDA's own list. Both constituents — BPC-157 and TB-500 — were placed in FDA's 503A "Category 2" in September 2023, but the FDA safety-risk page marked current through April 22, 2026 records that the nominations were withdrawn by their nominators; both peptides are no longer in Category 2, while FDA continues to display its safety concerns ^[10]. That placement took effect with the September 29, 2023 update to FDA's nominated-substances list, and Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding ^[10]. In plain terms, the list changed, but FDA has not said what a compounding pharmacy may now do with either peptide.

Nothing here states that any reclassification has happened. The July 2026 meeting was a discussion of candidate substances — a step in the process, and FDA has published no decision, listing, or outcome from it ^[12]. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply anything.

FDA's September 2023 Category 2 placement covered both BPC-157 and TB-500; the safety-risk page marked current through April 22, 2026 records that their nominators pulled the requests, while both peptides remain prohibited in sport by WADA. FDA has not said what the withdrawals mean for compounding access, and the July 23-24, 2026 PCAC meeting that listed both as candidates has no published vote record as of September 2026 ^[10][12].

What "Category 2" means under Sections 503A and 503B

Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight ^[11].

A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet listed are evaluated through a public nomination process ^[11].

Under FDA's interim policy, Category 2 bulk drug substances are those nominated with enough information to evaluate but which FDA identified as raising significant safety risks. Category 2 is not covered by the enforcement-discretion policy that applies to Category 1, and FDA stated it would consider taking action against a compounder using a Category 2 substance ^[10]. On January 7, 2025, FDA finalized a revised interim policy under which it no longer sorts newly nominated substances into these numbered categories; substances already in Category 2 are not afforded enforcement discretion even if nominations are updated ^[11]. Neither BPC-157 nor TB-500 is an FDA-approved drug — a separate question from compounding eligibility ^[11].

Which Wolverine peptides were on FDA's July agenda — and there is no carve-out

Both of Wolverine's components were on the July 2026 agenda; there was no component exception. FDA's public calendar listed BPC-157 and TB-500 (alongside KPV and MOTS-c) as bulk drug substances "being considered for inclusion on the 503A Bulks List" for the July 23-24, 2026 PCAC meeting ^[12].

The nominations for both peptides had been withdrawn before the July 2026 meeting, but FDA proceeded; agency staff proposed against adding either to the list, and FDA had posted no committee vote record when this page was checked in September 2026 ^[10][12]. BPC-157 appears as "BPC-157 (free base)" and "BPC-157 acetate" ^[10]. TB-500 is the substance FDA lists as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — FDA's own entry establishes that the marketed TB-500 is the LKKTETQ fragment of thymosin beta-4 ^[10]. Both placements took effect with the September 29, 2023 list update, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization ^[10].

Being discussed by PCAC was a step in evaluation, not a final listing decision, and FDA has published no outcome from the meeting — no result should be assumed or dated ^[12].

How legally compounded peptide access works

In the U.S., a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[11]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility ^[11].

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is one route to a licensed-prescriber consultation — not a separate legal status. Telehealth does not expand which substances may be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription ^[11].

The ingredient-eligibility caveat is the part that matters most for these two peptides. A compounded preparation may lawfully be made only when its active ingredient is permitted under the 503A/503B framework — a USP/NF monograph, a component of an approved drug, or a place on the applicable FDA bulks list. Ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[11]. BPC-157 and TB-500 no longer sit in Category 2 on FDA's page, yet FDA still shows its safety concerns beside them and has not said where that leaves a 503A pharmacy. This page does not name any pharmacy, clinic, telehealth provider, or vendor, and offers no dosing, administration instructions, or means of obtaining a restricted substance outside the lawful framework.

Is Wolverine legal?

Neither BPC-157 nor TB-500 is an FDA-approved drug for human use, and the Wolverine blend has no approved therapeutic indication ^[10][11]. Both were placed in FDA's 503A Category 2 in 2023 as potentially presenting significant safety risks; FDA's page now records their nominations as withdrawn, keeps those safety concerns beside them, and does not say what that means for a compounding pharmacy ^[10]. Both are also WADA-prohibited in sport.

Can you get BPC-157 from a compounding pharmacy?

FDA's safety-risk page records that BPC-157's nomination was withdrawn by its nominators and that the peptide is no longer in Category 2; the safety rationale remains, but FDA has not explained how a 503A pharmacy should read the withdrawal ^[10]. BPC-157 was also on the July 23-24, 2026 PCAC agenda as a candidate; FDA has published no record of the committee's votes as of September 2026 ^[12].

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use, and neither now appears in FDA's 503A Category 2 table for compounding, though FDA keeps its safety concerns listed beside both ^[10]. Both are also prohibited by the World Anti-Doping Agency: BPC-157 under the S0 non-approved-substances category, and TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories, banned in and out of competition.

What is the FDA 503A status of Wolverine?

FDA's safety-risk page records the withdrawal of the nominations for BPC-157 and TB-500; both constituents are no longer in Category 2, and FDA has not stated how those withdrawals bear on a 503A pharmacy's use of either ingredient ^[10]. Both were on the July 23-24, 2026 PCAC agenda as substances "being considered for inclusion on the 503A Bulks List"; FDA staff had proposed against adding them, and no listing decision or vote record has been published ^[12].